ABSTRACT
Advancements in percutaneous coronary intervention (PCI) and advent of newer generation drug eluting stents (DESs) have improved outcomes in patients with diabetes mellitus. This chapter reviews the revascularization strategy in patients with diabetes mellitus, with particular focus on the role of bioresorbable scaffold (BRS) in the patient group. Diabetic patients with less extensive coronary disease can be treated with PCI. Suitable lesion selection, in diabetics, is pivotal to reduce incidence of late target lesion revascularization (TLR) and stent thombosis, as polymeric BRSs come with entirely different strut structure and biomechanical properties. Bioresorbable vascular scaffold (BVS) have a bulky profile relative to modern generation DES due to thicker stent struts which can compromise the deliverability of the device through the diabetic coronary anatomy. Patients who are likely to need further revascularization may benefit from use of BRSs, so that future revascularization option with either PCI or CBAG remains possible.
